@article{JGO15058,
author = {Michael J. Dohopolski and Scott M. Glaser and John A. Vargo and Goundappa K. Balasubramani and Sushil Beriwal},
title = {Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer—patterns of care and overall survival},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {5},
year = {2017},
keywords = {},
abstract = {Background: Unresectable pancreatic cancer remains a challenging disease to treat. Stereotactic body radiotherapy (SBRT) allows for a higher biologically equivalent dose in an abbreviated course more convenient for patients and the integration of systemic therapy. We sought to investigate utilization trends and survival outcomes for patients treated with pancreatic SBRT versus conventionally fractionated radiotherapy (CFRT).
Methods: We engaged the National Cancer Database (NCDB) from 1998–2012 and identified locally-advanced unresectable patients with histologically confirmed, non-metastatic, pancreatic adenocarcinoma who received radiotherapy. Patients who received CFRT (1.5–4.0 Gy per fraction to a dose of ≥45 Gy, n=11,879) were compared to those who received SBRT (6–15 Gy per fraction to a dose of ≥20 Gy, n=474).
Results: Median follow-up was 11.0 months (18.4 months for survivors). SBRT utilization increased from 0.2% to 7.4% from 1998 to 2012 (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/15058}
}